XENE - Company ID 0001582313
Xenon Pharmaceuticals Inc. (XENE) reported revenue of $7.50M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $7.50M | - |
| FY 2024 | $0.00 | - |
| FY 2023 | $0.00 | -100.0% |
| FY 2022 | $9.43M | -48.8% |
| FY 2021 | $18.44M | -42.7% |
| FY 2020 | $32.17M | +371.0% |
| FY 2019 | $6.83M | +2095.8% |
| FY 2017 | $311.00K | -82.8% |
| FY 2016 |
Xenon Pharmaceuticals Inc. (XENE) reported revenue of $7.50M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, Xenon Pharmaceuticals Inc.'s revenue declined from $14.31M to $7.50M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.80M |
| -88.4% |
| FY 2015 | $15.58M | -45.1% |
| FY 2014 | $28.37M | +3.7% |
| FY 2013 | $27.36M | +91.2% |
| FY 2012 | $14.31M | - |